Tenaya Therapeutics, Inc.
TNYA · XNASCIK 1858848fmd_13SJ375FSVC647RJ9M5CFYC547Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Research and development | 31 | 54 | 95 | 98 | 87 | 69 |
| Total operating expenses | 39 | 73 | 126 | 131 | 116 | 93 |
| Operating income | (39) | (73) | (126) | (131) | (116) | (93) |
| Interest and investment income | 0 | 0 | 2 | 7 | 5 | 3 |
| Other non-operating income (expense) | 1 | 0 | 2 | 7 | 5 | 3 |
| Income before taxes | (38) | (73) | (124) | (124) | (111) | (91) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (38) | (73) | (124) | (124) | (111) | (91) |
| Net income | (38) | (73) | (124) | (124) | (111) | (91) |